Chronic Kidney Disease Chronic Kidney Disease
Conditions
Interventions
On-line hemodiafiltration therapy using ABH-22PA for six weeks.
Hemodiafiltration
Sponsors
OKADA Kazuyoshi
ASAHI KASEI MEDICAL CO., LTD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients on stable maintenance on-line hemodiafiltration therapy at least one month. 2) Patients with capable of obtaining blood flow rate >= 280 mL/min. 3) Patients who are undergoing hemodiafiltration with a hemodiafiler of membrane area >= 2.2m^2. 4) Patients who are undergoing hemodiafiltration for >= 4 hours per treatment. 5) Patients who are capable to participate in the study as outpatients. 6) Patients capable of understanding the informed consent form. 7) Patients >= 20 years and <85 years of age at the time of informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients requiring another blood purification therapy such as peritoneal dialysis other than hemodiafiltration within this study period. 2)Patients with a medical history of anaphylaxis symptoms caused by polysulfone or polyvinylpyrrolidone (PVP). 3)Patients who will participate in other clinical trials that may influence the results of this study within this study period. 4)Patients in the opinion of the principal investigator to disqualify from participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction rate, Removal amount, Clear space, Albumin leakage, Transmembrane pressure, Antithrombotic property | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory response | — |
Contacts
Public ContactHiroyuki MICHIWAKI
Kawashima Touseki clinic
Outcome results
None listed